Dutch firm Crucell last week announced that it has entered into an
agreement with vaccine specialist Sanofi Pasteur for its next
generation rabies antibody cocktail.
Crucell and DSM will further expand the development of its PER.C6
protein and monoclonal antibody licensing business by establishing
joint R&D centres on the US East Coast and in the Netherlands.
In the same week that saw Novartis threaten its planned merger with
Berna Biotech, Dutch biotech company Crucell has signed three new
licensing agreements for its PER.C6 and STAR manufacturing
technologies.
Dutch biotechnology company Crucell has announced a new project
aimed at developing a vaccine for West Nile virus, a flu-like
illness that can cause a brain infection with a mortality rate of 1
per cent